Akut Üriner Retansiyon ve Mesane Çıkım Obstrüksiyonu

European Association of Urology. EAU Guidelines on Urinary Retention. Arnhem: EAU Guidelines Office; 2024.

European Association of Urology. EAU Guidelines on Management of Non-neurogenic Male LUTS. Arnhem: EAU Guidelines Office; 2024.

European Association of Urology. EAU Guidelines on Benign Prostatic Obstruction. Arnhem: EAU Guidelines Office; 2024.

Emberton M, Fitzpatrick JM. The Reten-World survey of the management of acute urinary retention: preliminary results. BJU Int. 2008;101(3):347–351.

Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(2):481–487.

McNeill SA. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Urol. 2004;45(3):325–332.

McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreave TB. Sustained-release alfuzosin and trial without catheter after acute urinary retention. Rev Urol. 2004;6(Suppl 4):S7–S16.

Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. Nat Rev Urol. 2010;7(12):657–667.

Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient. Lancet Neurol. 2015;14(7):720–732.

Fitzpatrick JM, Kirby RS. Management of acute urinary retention. BJU Int. 2006;97(Suppl 2):16–20.

Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–1109.

Klahr S, Harris K, Purkerson ML. Obstructive nephropathy. N Engl J Med. 1988;318(12):776–783.

Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. Eur Urol. 2005;48(1):101–107.

Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase in men with benign prostatic hyperplasia. J Urol. 2002;168(4 Pt 1):140–145.

Gratzke C, Bachmann A, Descazeaud A, et al. Management of non-neurogenic male LUTS. Eur Urol. 2015;67(6):1099–1109.

Wyndaele JJ, Gammie A, Bruschini H, et al. Bladder management in neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2011;30(4):497–503.

Culkin DJ, Exaire EJ, Green D, et al. Anticoagulation and antiplatelet therapy in urological practice. J Urol. 2014;192(4):1026–1034.

European Association of Urology. EAU Guidelines on Urinary Retention. Arnhem: EAU Guidelines Office; 2024.

European Association of Urology. EAU Guidelines on Management of Non-neurogenic Male LUTS. Arnhem: EAU Guidelines Office; 2024.

European Association of Urology. EAU Guidelines on Benign Prostatic Obstruction. Arnhem: EAU Guidelines Office; 2024.

Emberton M, Fitzpatrick JM. The Reten-World survey of the management of acute urinary retention: preliminary results. BJU Int. 2008;101(3):347–351.

Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(2):481–487.

McNeill SA. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Urol. 2004;45(3):325–332.

McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreave TB. Sustained-release alfuzosin and trial without catheter after acute urinary retention. Rev Urol. 2004;6(Suppl 4):S7–S16.

Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. Nat Rev Urol. 2010;7(12):657–667.

Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient. Lancet Neurol. 2015;14(7):720–732.

Fitzpatrick JM, Kirby RS. Management of acute urinary retention. BJU Int. 2006;97(Suppl 2):16–20.

Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–1109.

Klahr S, Harris K, Purkerson ML. Obstructive nephropathy. N Engl J Med. 1988;318(12):776–783.

Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. Eur Urol. 2005;48(1):101–107.

Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase in men with benign prostatic hyperplasia. J Urol. 2002;168(4 Pt 1):140–145.

Gratzke C, Bachmann A, Descazeaud A, et al. Management of non-neurogenic male LUTS. Eur Urol. 2015;67(6):1099–1109.

Wyndaele JJ, Gammie A, Bruschini H, et al. Bladder management in neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2011;30(4):497–503.

Culkin DJ, Exaire EJ, Green D, et al. Anticoagulation and antiplatelet therapy in urological practice. J Urol. 2014;192(4):1026–1034.